A team from The Institute of Cancer Research, London, has developed a new immuno-PET imaging technique that could spot which ...

A new analysis of real-world data show that just as in solid tumors, higher tumor mutational burden (TMB) and PD-L1 expression in blood cancers are linked to less-optimistic prognoses.

Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.

BioNTech said that its VEGF bispecific sets it apart from competitors because of its mechanism and how it plans to ...

The global PD-L1 biomarker testing market is experiencing remarkable growth, fueled by the increasing demand for personalized ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

Three phase 3 trials will assess datopotamab deruxtecan-based treatments in patients with nonsquamous non-small cell lung ...

The drugmakers will explore the efficacy of Dato-DXd in combination with other drugs in PD-L1-expressing or EGFR-mutated NSCLC in these studies.

Mutation-directed targeted therapy in combination with a PD-L1 inhibitor “is a promising strategy” to extend survival in patients with anaplastic thyroid cancer, according to researchers.

Patients with TNBC and HR+/HER2- breast cancer demonstrated safe treatment with preoperative radiation therapy with Keytruda.

TACTI-003 Cohort B: Eftilagimod Alpha (Soluble LAG-3) and Pembrolizumab in First-Line Recurrent or Metastatic Head & Neck ...

Researchers from Zhejiang Jieyuan Med-Tech Co. Ltd. and collaborators have reported the design and preclinical characterization of a novel series of benzylamine derivatives acting as PD-1/PD-L1 ...